Premium
Non‐prescription supplement‐induced hepatitis with hyperferritinemia and mutation (H63D) in the HFE gene
Author(s) -
Fujii Hideki,
Takagaki Nobumasa,
Yoh Takaharu,
Morita Atsuhiro,
Ohkawara Tohru,
Yamaguchi Kanji,
Minami Masahito,
Sawa Yoshihiko,
Okanoue Takeshi,
Ohkawara Yasuo,
Itoh Yoshito
Publication year - 2008
Publication title -
hepatology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.123
H-Index - 75
eISSN - 1872-034X
pISSN - 1386-6346
DOI - 10.1111/j.1872-034x.2007.00266.x
Subject(s) - medicine , abnormality , gastroenterology , medical prescription , liver function tests , liver function , mutation , pathogenesis , hepatitis , gene mutation , gene , biology , genetics , pharmacology , psychiatry
A 55‐year‐old Japanese woman was hospitalized because liver function tests showed an abnormality. Transaminases and biliary enzymes were markedly elevated with hyperferritinemia. Her imaging tests revealed no significant abnormality. She had been taking various non‐prescription supplements for over approximately 6 months. After the supplements were discontinued her liver function gradually improved. This clinical course was suggestive of supplement‐induced hepatitis. She had no history of taking supplements containing iron, so it was interesting that she had hyperferritinemia. We examined C282Y and H63D, which are important mutations in theiron‐metabolizing gene, HFE . She was found to be heterozygous for the H63D mutation. The interaction between hyperferritinemia and supplements is unknown, but it can be speculated that some interaction between iron overload and supplements may have underlain the pathogenesis of her liver injury.